Kamada Ltd.’s KMDA shares declined almost 16% after the company decided to withdraw the marketing authorization application (MAA) for its inhaled formulation of Alpha-1 Antitrypsin (AAT) in the EU.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results